Table 1.
Patient characteristics
| Variables | Patients (n = 50) |
|---|---|
| Clinical factors | |
| Sex, male/female | 29/21 |
| Age (years) | 69 (32–84) |
| HBsAg, positive, n (%) | 2 (4.0) |
| HCV Ab, positive, n (%) | 7 (14) |
| Child–Pugh class, A/B | 48/2 |
| CEA (ng/mL) | 3.3 (0.4–133.1) |
| CA 19-9 (IU/mL) | 199.8 (0.7–3055.0) |
| Tumor size (cm) (radiographical) | 4.0 (1.0–14.0) |
| Treatment factors | |
| R0 resection, n (%) | 48 (96) |
| Surgical procedures | |
| Extended/major/minor hepatectomy | 22/22/6 |
| Morbidity, C-D class III/IV, n (%) | 12 (24) |
| Preoperative chemotherapy, n (%) | 0 |
| Adjuvant chemotherapy, present, n (%) | 30 (60) |
| Pathological factors | |
| Tumor differentiation | |
| Well/moderate/poor | 28/15/7 |
| Vascular invasion, present, n (%) | 34 (68) |
| Biliary invasion, present, n (%) | 24 (48) |
| Lymph node metastasis, present, n (%) | 15 (30) |
| Tumor number, multiple, n (%) | 15 (30) |
| Tumor size (cm) (pathological) | 3.5 (1.0–14.0) |
| AJCC stage, I/II/III/IV | 2/10/13/25 |
| KRAS mutation status | |
| Wild-type/mutated | 34/16 |
AJCC American joint committee on cancer/international union against cancer classification, CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, HBsAg hepatitis B virus surface antigen, HCV Ab hepatitis C virus antibody, R0 resection no macroscopic and microscopic tumor remaining, C-D Clavien-Dindo classification system